New Search

If you are not happy with the results below please do another search

30 search results for: amed

1

Amedisys: Caught Between a RAC and a Hard Place

Citron first reported on Amedisys over a year ago.  Never before have we received as much correspondence from former employees as we did after this story.  Last month, the market witnessed the abrupt resignations of two key executives from Amedisys.  In this post, Citron will shed some light on the “story behind the story” of […]

2

Seeking Healthy Returns in Amedisys? (NASDAQ:AMED)

Better get a Second Opinion…. Citron Research was first drawn to research Arthrocare because one division was running margins that wildly outperformed all their competitors.  After working countless hours with private investigators and reviewing hundreds of documents, we were able to draw a line to what we believe explained the extreme outperformance:  fraud on the […]

4

Cyberdyne — The Most Ridiculously Priced Stock In the World

Japanese Investors are ADVISED to EXERCISE EXTREME CAUTION Target Price: 300¥ — 85% Downside  With its share price ~ 2,000¥, Cyberdyne’s market cap exceeds $4 billion USD. The story of Cyberdyne MUST be told to the worldwide investment community. Cyberdyne (TYO:7779) CEO Yoshiyuki Sankai has become a cultural icon in Japan. With his “mad scientist” […]